<DOC>
	<DOCNO>NCT02894775</DOCNO>
	<brief_summary>Since early 1990s , evidence-based medicine play increasingly important role decision-making treatment patient cancer . The high level evidence attribute result randomize comparative study , public health authority require proof randomize therapeutic trial authorize use new treatment . Patients include therapeutic trial benefit either best current treatment ( control group ) treatment suppose present good similar efficacy , together extremely rigorous surveillance protocol . Inclusion randomize therapeutic trial represent optimal therapeutic strategy.In order optimize fight cancer , French public health policy lead progressive implementation successive nationwide `` Cancer Plans '' since 2003 . One objectives increase proportion patient include clinical research trial . Thus , fraction enrol France progressively increase remain low around 8 % 2010 . The current 2014-2019 plan aim expand inclusion 50,000 patient per year . In context socio-economic inequality concern resource , residence access service , identify factor determine inclusion trial turn highlight reason non-inclusion . The aim study determine , population level , influence demographic characteristic socio-economic status patient digestive cancer inclusion clinical trial . Between 2004 2010 , 4632 patient record Burgundy Digestive Cancer Registry . According balance score , 136 patient include clinical trial match 272 patient meet eligibility criterion trial . Deprivation measure ecological European deprivation index . A conditional multivariate logistic regression perform .</brief_summary>
	<brief_title>Factors Influencing Inclusion Digestive Cancer Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>patient digestive cancer reside Burgundy , France associate cancer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>